To learn more about ovarian cancer treatments, please visit [ Ссылка ]
Learn about MSK: [ Ссылка ]
CONNECT WITH MSK
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
Instagram: [ Ссылка ]
Request an appointment at MSK by calling 800-525-2225 or online at: [ Ссылка ]
New vaccines that mobilize the immune system against cancer cells may offer a new approach to preventing the recurrence of ovarian cancer. Medical oncologist Paul Sabbatini discusses several new vaccines in development at Memorial Sloan Kettering Cancer Center. The vaccines recognize certain substances found on the surface of ovarian cancer cells and either attack them directly or cause an immune response that selectively destroys them.
{partial transcript}
In the next 15 to 20 minutes, we’ll provide a clinical update on where we are with our vaccine program. I know that many people in the room are participating in them at this time. I do hope you find it interesting.
I think the first question to address is why do we think about vaccines in ovarian cancer? A little bit of it relates to the natural history of the disease. We know that vaccines work better in small disease states. If you look at ovarian cancer, when patients start their treatments, a primary treatment, a good proportion of them achieve a first clinical remission.
We know that some patients are cured and other patients will have a relapse. These patients can again reenter clinical remission and sometimes this cycle can go on for several times.
The groups of patients we want to talk about are in some form of remission – either first clinical remission or second remission.
By second or third remission, we mean someone who’s had a relapse and with additional treatment, they’ve gone back into a full clinical remission – normalcy 125 and normal CT imaging
